Clinical Trials
31 trialsNeoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
Sun Yat-sen University
Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.
West China Hospital
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
University of Chicago
Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma
Sun Yat-sen University
Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma
West China Hospital
Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC
West China Hospital
Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
neoCHANCE-1
West China Hospital
A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma
West China Hospital
Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
Peking University Hospital of Stomatology
neoCHANCE-2
West China Hospital
NEOSTART
Sun Yat-sen University
ACROPOLI
SOLTI Breast Cancer Research Group
Neoadjuvant Immunochemotherapy for LAOSCC
Huashan Hospital
A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma
Chengdu University of Traditional Chinese Medicine
A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus
West China Hospital
OSCC
Shanghai Zhongshan Hospital
Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.
Sun Yat-sen University
Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma
Tongji Hospital
Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma :A Single-arm, Prospective, Phase II Trial
Zhejiang University
The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC
Fifth Affiliated Hospital, Sun Yat-Sen University
PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer
West China Hospital
Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer
Tianjin Medical University Cancer Institute and Hospital
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
Sun Yat-sen University
RETICULA-NPC
Fudan University
A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma:The POTENTIAL Study
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University